Efficacy and Economic System Evaluation of Trimebutine Maleate Combined with Bifidobacterium Triple Viable Bacteria in the Treatment of Irritable Bowel Syndrome

GU Hong; KONG Lingxi; WANG Jue; WANG Hongmei; ZHENG Xiaoying; WANG Xin; SHAN Xuefeng; QIU Feng

doi:10.14009/j.issn.1672-2124.2020.11.018

您当前的位置：

首页 >

文章列表页 >

Efficacy and Economic System Evaluation of Trimebutine Maleate Combined with Bifidobacterium Triple Viable Bacteria in the Treatment of Irritable Bowel Syndrome

更新时间：2022-10-08

- Efficacy and Economic System Evaluation of Trimebutine Maleate Combined with Bifidobacterium Triple Viable Bacteria in the Treatment of Irritable Bowel Syndrome
- Vol. 20, Issue 11, Pages: 1350-1354(2020)
- 作者机构：
  
  1. 重庆医科大学附属第一医院药学部
  2. 重庆医科大学附属第一医院消化内科
  3. 陆军军医大学第一附属医院流行病学中心
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.11.018
  CLC： R956;R574.4
- Published：2020，
扫描看全文
[1]顾洪,孔令希,王珏,王红梅,郑晓英,王新,单雪峰,邱峰.马来酸曲美布汀联合双歧杆菌三联活菌治疗肠易激综合征的疗效及经济学系统评价[J].中国医院用药评价与分析,2020,20(11):1350-1354.

GU Hong, KONG Lingxi, WANG Jue, et al. Efficacy and Economic System Evaluation of Trimebutine Maleate Combined with Bifidobacterium Triple Viable Bacteria in the Treatment of Irritable Bowel Syndrome. [J]. 20(11):1350-1354(2020)
[1]顾洪,孔令希,王珏,王红梅,郑晓英,王新,单雪峰,邱峰.马来酸曲美布汀联合双歧杆菌三联活菌治疗肠易激综合征的疗效及经济学系统评价[J].中国医院用药评价与分析,2020,20(11):1350-1354. DOI： 10.14009/j.issn.1672-2124.2020.11.018.

GU Hong, KONG Lingxi, WANG Jue, et al. Efficacy and Economic System Evaluation of Trimebutine Maleate Combined with Bifidobacterium Triple Viable Bacteria in the Treatment of Irritable Bowel Syndrome. [J]. 20(11):1350-1354(2020) DOI： 10.14009/j.issn.1672-2124.2020.11.018.

摘要

目的:系统评价马来酸曲美布汀联合双歧杆菌三联活菌治疗肠易激综合征（irritable bowel syndrome

IBS）的有效性及经济性。方法:检索中国期刊网全文数据库、万方数据库、维普数据库、中国生物医学文献数据库等中文数据库和Pub Med、EMBase、Cochrane图书馆等英文数据库

检索时间为各数据库创建至2020年3月

纳入马来酸曲美布汀联合双歧杆菌三联活菌（研究组）对比单独使用马来酸曲美布汀（对照组）治疗IBS的随机对照试验研究

进行荟萃分析（Meta分析）。从医疗保健系统角度

采用成本-效果分析法对两种治疗方案进行经济学评价;并通过成本下浮10%及治疗有效率上下浮动10%进行敏感性分析。结果:纳入11篇文献

共1 312例患者。Meta分析结果显示

研究组患者的临床总有效率明显优于对照组

差异有统计学意义（RR=1.24

95%CI=1.18～1.30

P <0.000 01）;两组患者在治疗过程中均未出现严重药品不良反应。经济学评价结果提示

研究组方案的成本-效果比为256.52

且相对于对照组其增量成本-效果比为793.33

即当患者支付意愿≤793.33元时

对照组方案较优;当患者支付意愿> 793.33元时

研究组方案较优。敏感性分析结果显示

经济学评价结果较为稳定。结论:马来酸曲美布汀联合双歧杆菌三联活菌治疗IBS的临床疗效优于单独使用马来酸曲美布汀

临床医师可根据患者支付意愿选择是否联合用药。

Abstract

OBJECTIVE: To systematically evaluate the effectiveness and economics of trimebutine maleate combined with bifidobacterium triple viable bacteria in the treatment of irritable bowel syndrome（ IBS）. METHODS:CNKI

Wanfang database

VIP database

CBM

Pub Med

EMBase and the Cochrane Library were retrieved until Mar. 2020. Meta-analysis was performed on randomized controlled trials of efficacy of trimebutine maleate combined with bifidobacterium triple viable bacteria（ study group） versus trimebobutin maleate alone（ control group） in the treatment of IBS. From the perspective of medical care system

the cost-effectiveness analysis method was used to evaluate the economics of the two treatment regimens. The sensitivity analysis was carried out by cost decrease of 10%and treatment efficiency fluctuation of 10%. RESULTS: Totally 11 literature were collected

including 1 312 patients.Meta-analysis showed that the total clinical effective rate of the study group was significantly better than that of the control group

and the difference was statistically significant（ RR = 1. 24

95% CI = 1. 18-1. 30

P < 0. 000 01）. No severe adverse drug reactions were found in both groups. The economic evaluation results indicated that the costeffectiveness ratio of the study group regimen was 256. 52 and its incremental cost-effectiveness ratio was 793. 33 compared with the control group

that is

the control group scheme was better when the patient’s willingness to pay was ≤793. 33 yuan

when the patient’s willingness to pay was > 793. 33 yuan

the study group scheme was better.The results of sensitivity analysis showed that the results of economic evaluation were relatively robust.CONCLUSIONS: The clinical efficacy of trimebutine maleate combined with bifidobacterium triple viable bacteria in the treatment of IBS is better than that of trimebutine maleate alone

clinicians can choose whether to use combined regimen according to patients’ willingness to pay.

关键词

马来酸曲美布汀双歧杆菌三联活菌肠易激综合征Meta分析经济学评价

Keywords

Trimebutine maleateBifidobacterium triple viable bacteriaIrritable bowel syndromeMetaanalysisEconomics evaluation

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Rhizoma Atractylodes Macrocephala in Compatible with Radix Paeoniae Alba in the Treatment of Irritable Bowel Syndrome Based on Network Pharmacology

Systematic Review of Efficacy and Safety of Kuntai Capsules Combined with Hormone Replacement Therapy in the Treatment of Premature Ovarian Failure

Related Author

YAN Haidong

MIAO Wenqing

XU Qiaoxin

ZHANG Zhipeng

CAI Yanqu

DENG Qiaoyin

ZHAO Ying

YU Lili

Related Institution

Ward 2 of Gastrointestinal Surgery,Xianning Central Hospital/the First Affliated Hospital of Hubei University of Science And Technology

School of Traditional Chinese Medicine,Guangdong Pharmaceutical University

Center for New Drug Research and Development,Guangdong Pharmaceutical University

College of Pharmacy,Hubei University of Science and Technology

Key Laboratory of Modern Chinese Medicine, Provincial Education Department of Guangdong

⁰